solomon retweeted
#ICYMI: $CLDI's CEO Eric Poma, Ph.D. spoke with BioPharma Boardroom about the #RedTail platform, CLD-401 and Calidi’s approach to reaching primary and metastatic tumors.
🔗: bit.ly/4vXCQw5
solomon retweeted
In a recent Talking Biotech episode, $CLDI's CEO & Director Eric Poma, Ph.D. discusses Calidi’s systemic #oncolyticvirus platform and CLD-401, designed to avoid immune clearance and selectively replicate in tumor cells.
Listen on @ApplePodcasts: apple.co/3Vfxhg4
solomon retweeted
In a interview with @RedChip Eric Poma, Ph.D. discusses $CLDI's #RedTail platform & CLD-401, designed to target and lyse tumor cells while delivering an IL-15 superagonist to help activate an anti-cancer immune response.
Watch the clip & full interview: bit.ly/3T59XQ
solomon retweeted
In a new Q&A with @ClinicalLeader1, $CLD's CEO Eric Poma, Ph.D. discusses the science behind CLD-401 and the strategy behind its planned Phase 1 study.
Read more: bit.ly/3U8cLO5
#OncolyticViruses #Oncology #Biotech
solomon retweeted
$CLDI's CEO Eric Poma, Ph.D. joined @kevinfolta to discuss the potential of #oncolyticviruses for solid tumors and Calidi’s vaccinia-based approach designed to reach tumors and stimulate an immune response.
Listen on @ApplePodcasts: apple.co/3Vfxhg4
#Oncology,
solomon retweeted
Reaching metastatic tumors remains a major challenge for oncolytic virotherapy.
$CLDI's CEO Eric Poma, Ph.D. discusses why systemic delivery matters and how newer approaches may help therapies reach #tumors more effectively with @LifeScienceDN
Read more: bit.ly/4xTDk7E
solomon retweeted
$CLDI’s CLD-401 is designed to home to metastatic tumor sites, induce tumor cell lysis and immune priming, and support local production of an IL-15 superagonist to help generate an anti-tumor immune response.
Learn more about our science: bit.ly/4d89lR5
solomon retweeted
This #WorldCancerResearchDay, $CLDI honors the researchers, clinicians and innovators advancing new approaches for patients with cancer.
Continued research is essential to creating new possibilities and improving the future of cancer care.
#CancerResearch
solomon retweeted
Earlier this month, $CLDI's CEO Eric Poma, Ph. shared his perspective with Drug Discovery Online on the future of cancer drug discovery and targeted immune activation.
Read more: bit.ly/4iFtPVt
solomon retweeted
In this #NanoCapPodcast clip, $CLDI's CEO Eric Poma discusses progress toward an #IND application and plans to begin clinical studies following the regulatory process.
Watch the clip and listen to the full episode here: bit.ly/4gumW83
solomon retweeted
What is an IL-15 superagonist, and how does it connect to $CLDI’s lead program, CLD-401?
CLD-401 is designed to produce IL-15 superagonist at the tumor, helping activate immune cells and support an anti-tumor immune response.
solomon retweeted
Meet Antonio F. Santidrian, PharmD, Ph.D., CSO and Head of Technical Operations at $CLDI.
Since joining Calidi in 2015, Antonio has led R&D and is a coinventor of the RedTail Platform, bringing 20+ years of anti-cancer translational research experience.
solomon retweeted
$CLDI’s CEO, Eric Poma, Ph.D., will hold one-on-one meetings with investors at @HCWCO's 28th Annual Global Investment Conference. A virtual presentation will be available on-demand for registered attendees via the conference platform starting 9/11/26.
🔗 bit.ly/3SOk1hC
solomon retweeted
What’s next for Cancer Drug Discovery?
In a new #DrugDiscovery Online article, $CLDI's CEO Eric Poma, Ph.D. discusses targeted immune activation, drug delivery and Calidi’s approach with CLD-401.
Read more: bit.ly/4iFtPVt
solomon retweeted
#ICYMI: In a recent @Xtalks feature, $CLDI's CEO Eric Poma, Ph.D., discussed the future of systemically delivered oncolytic virotherapy and Calidi's approach to targeted delivery for #metastaticcancer.
Read more: bit.ly/4eMnGo4
solomon retweeted
Today we're spotlighting $CLDI's Board of Directors, whose expertise spans biotechnology, clinical development, and corporate leadership.
Learn more: bit.ly/4g36fAJ
#BoardOfDirectors
solomon retweeted
August is #WorldCancerSupportMonth.
$CLDI recognizes the strength of patients, caregivers, healthcare professionals, and advocates while continuing to advance innovative targeted genetic medicines for the future of #cancercare.
solomon retweeted
Following last week's Q2 update, $CLDI continues to advance its RedTail platform and pipeline.
Q2 highlights included regulatory progress for CLD-401, new platform data and progress toward first patient dosing in Q1 2027.
🔗: bit.ly/4qqfL47
#Biotech
solomon retweeted
$CLDI reported Q2 2026 results, including positive FDA pre-IND feedback for CLD-401 and new CLD-501 data presented at @ASCO.
Calidi anticipates CLD-401 entering the clinic in Q1 2027 while advancing its #RedTail platform.
🔗: bit.ly/4qqfL47
solomon retweeted
Learn more about $CLDI's RedTail platform and the Company's vision in CEO Eric Poma's interview with @RedChip.
Full interview on @YouTube: bit.ly/3T59XQM
Calidi Biotherapeutics (NYSE-A: CLDI): FDA Discussions Support Strategy and Timeline for CLD-401 IND Filing in 2026
Calidi Biotherapeutics has provided a mid-year update confirming that discussions with the FDA have been productive and are supportive of both the company's regulatory strategy and its timeline for submitting an Investigational New Drug (IND) application for CLD-401, its lead cancer therapy candidate. The candidate is designed to be delivered through the bloodstream and is engineered to find and replicate inside metastatic tumor sites while delivering an immune-activating signal called an IL-15 superagonist, which is a molecule that turns up the immune system's ability to attack cancer cells.
In parallel, Calidi is expanding its pipeline to include a next-generation approach using in situ T-cell engagers — a technique designed to recruit the body's own immune cells to attack tumors from inside the tumor environment, rather than systemically, which has historically caused toxicity problems in other therapies.
Why Investors Should Be Watching:
- Regulatory validation: Productive FDA dialogue is a meaningful de-risking signal — it suggests the agency has no major objections to the current development path, reducing uncertainty around the IND submission
- 2026 IND target: A successful IND filing this year would clear the path for first-in-human trials, the next major value inflection point for a clinical-stage biotech
- Pipeline depth: The addition of in situ T-cell engager technology expands the RedTail platform's potential addressable indications beyond CLD-401's current targets
- Execution signal: The mid-year update frames this as on-track progress, not a course correction — a meaningful distinction for a pre-revenue, clinical-stage company
For the full press release: redchip.news/4pR3CFj
#CLDI #CaldiBiotherapeutics #Biotech #Oncology #SmallCapBiotech #CancerResearch #ImmunOncology #NYSEAmerican #ClinicalStage













